March 2018, she is appointed as Pivot Park and Pivot Park Screening Centre’s CEO. Brigitte worked in different roles for Organon, Alliance Health Care, Polos and Orly Pharma a.o. She gained experience in the preparation and introduction of medicines on the market, consultancy regarding entrepreneurship and general management. Thanks to her comprehensive experience within several boards and networking organisations she is an experienced and excellent connector. She received her master degree in Pharmacy at Utrecht University in 1992 and her Master of Business Administration at Tias Business School in 1997.
With more than 30 years of experience in the pharmaceutical industry, Stan van Boeckel was appointed Chief Scientific Officer of PPSC in June 2012. His experience ranges from small molecules to bioconjugates. Among other accomplishments, his work at Organon led to the introduction of the new antithrombotic drug Arixtra®. From 1997‐2004 he was responsible for a new Lead Discovery Unit at Organon comprising HTS facilities, assay development and Hit-to- Lead Chemistry. In the period 2004‐2011 he was Head of Medicinal Chemistry at Organon/ MSD in Oss. He received his doctorate in bio‐organic chemistry in 1982 at Leiden University. He has held a professorship at Leiden University since 1993.
Helma Rutjes is currently employed as Chief Operations Officer at PPSC. She has a solid background in Medical Biology in fields ranging from neurology, developmental biology and diabetes, to innate immunity and cancer. While working towards her doctorate (1996-2001) on Alzheimer’s disease and a subsequent post-doctorate on renal cell carcinomas (2000-2006), she gained ample experience in cell biology, molecular biology and biochemistry. From 2006 to 2013, she worked as Head of Research & Development at Hycult Biotech, a Dutch Biotech company focused on assays, antibodies and proteins in the field of innate immunity. In 2013 she joined PPSC and contributed to the success of the European Lead Factory as WP-lead Assay Development.
Steven van Helden has a twenty five-year history in the pharmaceutical industry and was a fundamental actor in the founding of PPSC. He obtained his doctorate in pharmaceutical chemistry in 1992 and then joined Organon’s molecular modelling department. Using chemoinformatics and database technologies, he contributed to a range of research projects, mainly in the field of nuclear receptors. After two years in Newhouse, Scotland, where he streamlined compound selection and acquisition for screening, he returned to Oss to become head of Screening & Technologies. In this function, he set up a new infrastructure for in-vitro screening, ran screening operations for nine years and, after two US take-overs, contributed to a screening strategy for the new combined company.
Ronald ten Berge has more than 23 years of experience in sales, marketing, business development and account management in pharma companies and contract research organizations. This entrepreneur (he founded his consultancy company Montagne Pharma in 2014) with scientific background (PhD in pharmacology, 1994) has gained extensive knowledge of drug discovery and development and created a large global network. As Chief Business Officer and in his communication with customers and external partners Ronald can perfectly balance between sales, science and management. Together with the other MT members he developed the company’s strategy. At PPSC he is responsible for sales & marketing, account management, communication and networking with other companies in Drug Discovery.